ArticleInternational journal of retina and vitreous2025
Automated fluid monitoring to optimize the follow-up of neovascular age-related macular degeneration patients in the Brazilian population.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the efficacy of an artificial intelligence (AI)-based fluid monitoring tool in optimizing the monitoring of neovascular age-related macular degeneration (nAMD) patients in a Brazilian cohort.
methodsThis is a retrospective real-world study performed in a tertiary center in Brazil, including patients with nAMD. Spectral-domain optical coherence tomography (Spectralis, Heidelberg Engineering, Germany) images were processed at baseline and over 2 years of follow-up. Demographic and clinical data were collected. A deep learning algorithm (Fluid Monitor, RetInSight, Austria) was used to automatically quantify intraretinal fluid (IRF), subretinal fluid (SRF) and pigment epithelial detachment (PED). A longitudinal panel regression model and Log-Rank test were performed to assess the correlation between fluid volumes and treatment frequency, visual outcomes, macular atrophy (MA) and subretinal fibrosis (SF) development.
resultsNinety-nine eyes from 84 patients were included. Fifty-eight eyes were treatment-naïve. Higher IRF and PED in the 6 mm area were correlated with worse visual outcomes over a 2-year follow-up (p = 0.01 and p < 0.001, respectively). Higher IRF, SRF and PED were correlated with an increased risk of SF development (p < 0.001, p = 0.049 and p = 0.02 respectively). MA development showed no significant correlation with higher IRF, SRF nor PED in this analysis. Higher SRF volume correlated with a greater number of required intravitreal injections over 2-years.
conclusionThis study investigates the multifaceted landscape of nAMD in a tertiary center in the Southeast Brazil using an AI-based fluid monitoring tool. Further studies that highlight the significance of using newly validated technologies across diverse populations worldwide will be of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.